Valuation: Cell Source, Inc.

Market Cap 24.41M 21.79M 20.05M 18.2M 34.49M 2.29B 35.34M 240M 95.6M 1.22B 91.62M 89.66M 3.86B P/E 2023
-2.65x
P/E 2024 -2.49x
Enterprise Value 34.92M 31.17M 28.68M 26.03M 49.33M 3.27B 50.56M 343M 137M 1.75B 131M 128M 5.52B EV / Sales 2023
-
EV / Sales 2024 -
Free-Float
80.32%
Yield 2023 *
-
Yield 2024 -
1 day-23.06%
1 week-24.51%
Current month-24.51%
1 month-26.65%
3 months-51.42%
6 months-52.38%
Current year-20.00%
1 week 0.38
Extreme 0.375353
0.52
1 month 0.38
Extreme 0.375353
0.53
Current year 0.25
Extreme 0.25
2.25
1 year 0.25
Extreme 0.25
2.25
3 years 0
Extreme 0.0002
2.25
5 years 0
Extreme 0.0002
2.25
10 years 0
Extreme 0
2.55
Manager TitleAgeSince
Chief Executive Officer 66 2014-06-29
Director TitleAgeSince
Chairman 77 2015-05-17
Director/Board Member 82 2021-03-24
Director/Board Member 72 2022-03-09
Date Insider Type Main position Quantity % Market Cap. Importance
8/9/21 Others

Director

800,000 2.4492%
6/30/21 Others

Director

4,860 0.0149%
6/30/21 Others

Chairman

2,976 0.0091%
Change 5-day change 1-year change 3-year change Capi.($)
-23.06%-24.51%+2.56%-42.03% 35.8M
+2.24%+8.40%+58.47%+69.00% 66.7B
+4.66%+8.90%+16.93%+85.41% 56.88B
-0.60%+1.73%+24.32%+94.40% 56.53B
+2.55%+15.52%+30.43%+120.17% 46.49B
+2.58%+7.89%+32.49%+45.30% 44.8B
+4.09%+6.37%+228.06%+899.75% 41.59B
-0.47%+9.38%+27.53%+52.40% 35.35B
+3.80%-1.00%+98.16%+66.79% 33.29B
+1.48%+6.21%-38.80%+395.73% 25.1B
Average -0.27%+5.97%+48.02%+178.69% 41B
Weighted average by Cap. +2.29%+7.27%+53.74%+181.53%

Financials

2023 2024
Net sales - -
Net income -5.32M -4.75M -4.37M -3.97M -7.52M -499M -7.7M -52.28M -20.84M -267M -19.97M -19.55M -841M -4.51M -4.03M -3.71M -3.36M -6.38M -423M -6.53M -44.34M -17.67M -226M -16.94M -16.58M -713M
Net Debt 9.27M 8.28M 7.62M 6.91M 13.1M 869M 13.43M 91.12M 36.32M 465M 34.81M 34.06M 1.47B 10.51M 9.38M 8.63M 7.83M 14.85M 985M 15.21M 103M 41.15M 527M 39.44M 38.6M 1.66B
Projected Income Statement - Annual - Cell Source, Inc.
Logo Cell Source, Inc.
Cell Source, Inc. is a cell therapy company focused on immunotherapy. The Company is primarily focused on the development of immune system management technology (Veto Cell technology). Its lead prospective product is its Veto Cell immune system management technology. Its Veto Cell technology is an immune tolerance biotechnology that enables the selective blocking of immune responses. Its Veto Cell technology is in pre-clinical phase, and its data shows that it provides results in allogeneic (donor-derived) hematopoietic stem cell transplantation (HSCT) by allowing for haploidentical stem cell transplants under a mild conditioning regimen. Its product pipeline includes chimeric antigen receptor (CAR) T-cell therapies, which include VETO CAR-T (with or without HSCT) for B-cell malignancies, Veto Cell kidney transplants, VETO CAR-T for solid tumors, Veto Cell liver transplants, and Veto HSCT for non-malignant disorders. The Company's wholly owned subsidiary is Cell Source Limited (CSL).
Employees
-
Date Price Change Volume
26-11-09 $0.4000 -23.06% 7,470
26-11-04 $0.5199 +23.67% 1,100
  1. Stock Market
  2. Stocks
  3. CLCS Stock